Founded July 2015
Stage Business development
Investors The Trendlines Group, Pix Vine Capital, private and strategic investors
CEO Omer Zelka
ElastiMed is developing a compression stocking, made from smart materials, that mimics rhythmic calf muscle contractions and stimulates blood flow. Based on proprietary technology that utilizes Electro-Active Polymers (EAPs), ElastiMed’s stocking stretches and contracts when stimulated by an electric pulse (generated by a 3V battery).
These unique characteristics, combined with low-cost materials and a high level of control, enable the ElastiMed stocking to provide patients with a highly effective, easy-to-wear, and affordable treatment option. Read more about the idea behind the ElastiMed stocking.
There is a clear need in the compression therapy market for increased compliance, which improves treatment and prevents symptoms such as swelling, blood clots, and leg ulcers from returning.
Watch the interview with CEO Omer Zelka on ILTV.
Watch Omer Zelka's interview on Start-Up Stadium (Hebrew).
CEO Omer Zelka presents at a Trendlines Showcase.
Extensive experience with electro-active materials; engineer, Intel Corporation; BSc, electrical engineering, Ben-Gurion University of the Negev
5 years R&D experience with medical device and pharmaceutical companies; PhD, biotechnology, Technion-Israel Institute of Technology
Over 20 years of experience in developing and bringing medical devices to market; specialized in optimizing and scaling up production (Medinol, Motus GI Medical)
Private investor; former GM (Israel) and SVP, Paradigm (sold to Apax for $1 billion in 2012), and CEO, Odigo (acquired by Comverse for $20 million in 2002); former corporate attorney, Skadden Arps, New York City; LLM, NYU School of Law; LLB, Hebrew University of Jerusalem
Department of Surgery, Palmetto Health/University of South Carolina School of Medicine; former chairman, Vascular Surgery, Cleveland Clinic
Professor, mechanical engineering and biomedical engineering, Ben-Gurion University of the Negev; president, Israel Society for Theoretical and Applied Mechanics; former chairperson, Biomedical Engineering Department, Ben-Gurion University; expert in electroactive materials, mechanics of soft tissues, composite materials, and solid mechanics
Director, Vascular & Endovascular Surgery Department, Sheba Medical Center
Vascular surgeon; CEO & Founder, SerenaGroup; president-elect, Association for the Advancement of Wound Care (AAWC); past president, American Professional Wound Care Association; VP, American College of Hyperbaric Medicine
Dermatologist; professor, dermatology and phlebology, owner, Medical Consult Freiburg; CEO, AMED Freiburg; former VP, Department of Dermatology, University of Freiburg
A 60% noncompliance rate for existing treatment options. Chronic leg swelling (edema), which is caused by poor circulation, affects more than 7.4 million people in the United States alone1. Edema may result from old age, cancer treatments, poor diet or pregnancy. Blood clots, which are formed in the legs (DVT, deep vein thrombosis), affect over 790,000 people in the United States and EU2. Applying constant or changing external pressure on the legs has been proven to be a highly effective treatment to improve circulation and reduce swelling3. With a more than 60% non-compliance4 rate for existing treatment options, ElastiMed’s device is aimed at improving patient compliance with a comfortable, highly effective clinical treatment.
An estimated $3 billion market. ElastiMed addresses a potential global market of $3.3 billion. Leading players include BSN Medical, DJO, Medi, Medtronic, Sigvaris, Tactile Medical.